<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00995423</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0497</org_study_id>
    <nct_id>NCT00995423</nct_id>
  </id_info>
  <brief_title>Comparison of Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting Stent</brief_title>
  <acronym>PIPA</acronym>
  <official_title>Comparison of the Efficacy and Safety of Paclitaxel-Eluting CoroflexTM Please Stent Versus Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the outcome of treatment with CoroflexTM&#xD;
      Please stent is not inferior to the outcome of treatment with TAXUS stent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To establish the effectiveness and the safety of coronary stenting with the newly developed&#xD;
      paclitaxel-eluting balloon expandable stent (CoroflexTM Please stent, B. Bran, Melsungen,&#xD;
      Germany), compared to the conventional paclitaxel-eluting balloon expandable stent (TAXUS&#xD;
      stent, Boston scientific) in the treatment of coronary stenosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late lumen loss by quantitative coronary angiographic measurements</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (all and ischemia-driven)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (all and ischemia-driven)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (by ARC definition)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent late loss at 9 month angiographic follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis in both in-stent and in-segment</measure>
    <time_frame>9 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic pattern of restenosis</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success defined as achievement of a final diameter stenosis of &lt;30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion</measure>
    <time_frame>during the hospital stay</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CoroflexTM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>highly flexible CoroflexTM Please-Stent features</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAXUS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoroflexTM Please</intervention_name>
    <description>highly flexible CoroflexTM Please-Stent</description>
    <arm_group_label>CoroflexTM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel-eluting stent</intervention_name>
    <description>Paclitaxel-eluting stent</description>
    <arm_group_label>TAXUS</arm_group_label>
    <other_name>Taxus liberte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must be at least 18 years of age&#xD;
&#xD;
          -  Significant de novo coronary artery stenosis (&gt;50% by visual estimation)&#xD;
&#xD;
          -  Patients with stable (CCS class 1 to 4) or acute coronary syndromes (unstable angina&#xD;
             pectoris Braunwald class IB, IC, IIB, IIC, IIIB, IIIC or NSTEMI) or patents with&#xD;
             atypical chest pain or without symptoms but having documented myocardial ischemia,&#xD;
             amenable to stent-assisted percutaneous coronary intervention&#xD;
&#xD;
          -  The patient or guardian agrees to the study protocol and the schedule of clinical and&#xD;
             angiographic follow-up, and provides informed, written consent, as approved by the&#xD;
             appropriate Institutional Review Board/Ethical Committee of the respective clinical&#xD;
             site&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has a known hypersensitivity or contraindication to any of the following&#xD;
             medications:&#xD;
&#xD;
               -  Heparin&#xD;
&#xD;
               -  Aspirin&#xD;
&#xD;
               -  Both Clopidogrel and TIclopidine&#xD;
&#xD;
               -  Sirolimus, paclitaxel&#xD;
&#xD;
               -  Stainless steel and/or&#xD;
&#xD;
               -  Contrast media (patients with documented sensitivity to contrast which can be&#xD;
                  effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be&#xD;
                  enrolled. Patients with true anaphylaxis to prior contrast media, however, should&#xD;
                  not be enrolled)&#xD;
&#xD;
          -  Systemic (intravenous) Sirolimus or paclitaxel use within 12 months&#xD;
&#xD;
          -  Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
             possibly plan to become pregnant any time after enrollment into this study&#xD;
&#xD;
          -  History of bleeding diathesis or known coagulopathy (including heparin-induced&#xD;
             thrombocytopenia), or will refuse blood transfusions&#xD;
&#xD;
          -  Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery&#xD;
             within 2 months&#xD;
&#xD;
          -  Current known current platelet count &lt;100,000 cells/mm3 or Hgb &lt;10 g/dL&#xD;
&#xD;
          -  An elective surgical procedure is planned that would necessitate interruption of&#xD;
             thienopyridines during the first 12 months post enrollment&#xD;
&#xD;
          -  Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment)&#xD;
&#xD;
          -  Patients who are actively participating in another drug or device investigational&#xD;
             study, which have not completed the primary endpoint follow-up period&#xD;
&#xD;
          -  Patients with EF&lt;25%&#xD;
&#xD;
          -  Cardiogenic shock at entry&#xD;
&#xD;
          -  Acute MI patients within symptom onset &lt; 12 hours needing primary angioplasty&#xD;
&#xD;
          -  Creatinine level &gt; 3.0mg/dL or dependence on dialysis&#xD;
&#xD;
          -  Patients with left main stem stenosis (&gt;50% by visual estimate)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>GangNeung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kwangju Christian Hospital</name>
      <address>
        <city>Kwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>PyeongChon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hangang Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Veterans Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>October 14, 2009</study_first_submitted>
  <study_first_submitted_qc>October 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2009</study_first_posted>
  <last_update_submitted>August 17, 2010</last_update_submitted>
  <last_update_submitted_qc>August 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Seung-Jung Park</name_title>
    <organization>CardioVascular Research Foundation</organization>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

